|1.||Nagasawa, Hideko: 5 articles (02/2015 - 11/2003)|
|2.||Uto, Yoshihiro: 4 articles (12/2006 - 11/2003)|
|3.||Hori, Hitoshi: 4 articles (12/2006 - 11/2003)|
|4.||Ohnishi, Ken: 2 articles (02/2015 - 08/2005)|
|5.||Uto, Y: 2 articles (12/2006 - 06/2005)|
|6.||Nagasawa, H: 2 articles (12/2006 - 06/2005)|
|7.||Hori, H: 2 articles (12/2006 - 06/2005)|
|8.||Nagata, Kenji: 2 articles (02/2006 - 08/2005)|
|9.||Suzuki, Minoru: 2 articles (02/2006 - 08/2005)|
|10.||Masunaga, Shin-Ichiro: 2 articles (02/2006 - 08/2005)|
02/20/2015 - "The expressions of HIF-1α and HIF-2α induced under hypoxia were repressed by TX-402 in a dose-dependent manner. "
11/01/2004 - "The compound 3-amino-2-quinoxalinecarbonitrile 1,4-dioxide (4) displays potent hypoxia-selective cytotoxicity in cell culture. "
11/01/2003 - "TX-402 had more potent hypoxia-selective cytotoxicity than TPZ in either cell regardless of p53 status. "
02/20/2015 - "Its inhibition of hypoxia-induced CSC expansion makes TX-402 promising agent usable in combination for ovarian cancer therapy."
02/20/2015 - "TX-402, an analogue of tirapazamine, has been developed as a hypoxia selective prodrug with inhibitory effects of HIF-1 and angiogenesis. "
01/01/2012 - "Many of these new compounds displayed more potent hypoxic cytotoxic activity compared with TX-402 and TPZ in the tumor cells based evaluation, which confirmed our hypothesis that the replacement of the 3-amine with the substituted aryl ring of TX-402 increases the hypoxic anti-tumor activity. "
08/01/2005 - "The sensitivity to TX-402 was significantly higher than that to TPZ in both total and Q tumor cells of both tumors. "
11/01/2003 - "We have reported that hypoxic cytotoxins, such as TX-1102, tirapazamine (TPZ) and TX-402, selectively induced tumor cells to p53-independent apoptosis under hypoxic conditions and inhibited angiogenesis. "
12/01/2006 - "Based on these considerations, we developed the antiangiogenic hypoxic cell radiosensitizers, TX-1877, TX-1898 and the hypoxic cytotoxin TX-402 that inhibits the HIF-1alpha pathway We will also discuss our research involved with the development of other drugs to exploit tumor hypoxia, including a hypoxia-targeting boron carrier for boron neutron capture therapy (BNCT) and a p53 inhibiting radiosensitizer."
|3.||Ovarian Neoplasms (Ovarian Cancer)
|4.||Hepatocellular Carcinoma (Hepatoma)
06/01/2005 - "To evaluate the usefulness of continuous administration of hypoxic cytotoxins in terms of targeting acute hypoxia in solid tumours and the significance of combination with mild temperature hyperthermia (MTH) (40 degrees C, 60 min), the cytotoxic effects of singly or continuously administered tirapazamine (TPZ) and TX-402 were examined in combination with or without MTH in vivo. "
|1.||tirapazamine (SR 4233)
|6.||mercaptoundecahydrododecaborate (borocaptate sodium)
|1.||Boron Neutron Capture Therapy